ClinicalTrials.gg
CompletedNCT00545688Updated Aug 15, 2017Results posted

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

A Phase 2 interventional study of Herceptin and Docetaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 77 sites in 18 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jun 2006, registered Oct 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
417
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
45th of 366
417 · median 61
Started
2006
with 17 others
Phase 2
239 of 374
44 open now
Registered
109th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 45th largest by enrollment of the 366 interventional ones that give a count, is one of 18 that started in 2006, is one of 239 in phase 2, and was the 109th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This 4 arm study will evaluate the efficacy and safety of 4 neoadjuvant treatment regimens in female patients with locally advanced, inflammatory or early stage HER2 positive breast cancer. Before surgery, patients will be randomized to one of 4 treatment arms, to receive 4 cycles of a)Herceptin + docetaxel b)Herceptin + docetaxel + pertuzumab c)Herceptin + pertuzumab or 4)pertuzumab + docetaxel. Pertuzumab will be administered at a loading dose of 840mg iv, then 420mg iv 3-weekly, Herceptin at a loading dose of 8mg/kg iv then 6mg/kg 3-weekly, and docetaxel at a dose of 75mg/m2 escalating to 100mg/m2 3-weekly. During the entire pre- and post-surgery period all patients will receive adequate chemotherapy as per standard of care, as well as any surgery and/or radiotherapy as required. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients, >=18 years of age;
  • locally advanced, inflammatory or early stage invasive breast cancer;
  • positive (HER2+++ by IHC or FISH/CISH+).

Exclusion criteria

Exclusion Criteria:

  • disease (Stage IV) or bilateral breast cancer;
  • previous anticancer therapy or radiotherapy for any ;
  • other malignancy, other than cancer in situ of the cervix, or basal cell cancer;
  • insulin-dependent diabetes;
  • cardiovascular disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
417 participants (actual)

Study arms

  • Experimental
    1

    Drug: Herceptin · Drug: Docetaxel

  • Experimental
    2

    Drug: Herceptin · Drug: Docetaxel · Drug: Pertuzumab

  • Experimental
    3

    Drug: Herceptin · Drug: Pertuzumab

  • Experimental
    4

    Drug: Docetaxel · Drug: Pertuzumab

Interventions

  • 8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly

    Also known as: Trastuzumab

  • 75mg/m2 iv escalating to 100mg/m2 iv 3-weekly

  • 840mg iv loading dose, followed by 420mg iv 3-weekly

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Pathological Complete Response (pCR)

    pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders

    Time frame: Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)

  2. Percentage of Participants Achieving pCR by Breast Cancer Type

    pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Based on the type of breast cancer participants were categorized as those with 1. Operable breast cancer, 2. Inflammatory breast cancer and 3. Locally advanced breast cancer. Participants with invalid/missing pCR assessments were defined as non-responders.

    Time frame: Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)

  3. Percentage of Participants Achieving pCR by Hormone Receptor Status

    pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants were classified as Estrogen and/or Progesterone positive (+ve), Estrogen and/or Progesterone negative (-ve) or receptor status unknown. Participants with invalid/missing pCR assessments were defined as non-responders.

    Time frame: Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)

  4. Percentage of Participants Achieving pCR by Lymph Node Status

    pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Lymph node status was defined as either negative lymph node at surgery or positive lymph node at surgery. Participants with invalid/missing pCR assessments were defined as non-responders.

    Time frame: Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)

  5. Percentage of Participants Achieving pCR by Presence or Absence of Residual Intraductal Carcinoma (DCIS) / Intalobular Carcinoma (LCIS)

    pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders.

    Time frame: Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)

Secondary outcomes

  1. Percentage of Participants Achieving Best Primary Tumor Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Disease Progression [PD]) During Neo-Adjuvant Treatment by X-Ray/Mammography

    Tumor assessments were made based upon the Response Evaluation Criteria in Solid Tumors (RECIST) criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for primary breast tumor using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is greater than (\>)0 at screening or cycle 1 Day 1; PR: if measurement is at least a 30 percent (%) decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline.

    Time frame: Baseline up to Cycle 4 (assessed at, Baseline and Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months

  2. Percentage of Participants Achieving Best Overall Response (CR, PR, SD or PD) During Neo-Adjuvant Period by X-Ray/Mammography

    Tumor assessments were made based on the RECIST criteria - version 1.0 The overall response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.

    Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months

  3. Percentage of Participants Achieving Best Primary Breast Tumor Response (CR, PR, SD or PD) During Neo-Adjuvant Period by Clinical Examination

    Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for primary breast tumor using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.

    Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months

  4. Percentage of Participants Achieving Best Overall Response (CR, PR, SD or PD) During the Neo-Adjuvant Period by Clinical Examination

    Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.

    Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months

  5. Percentage of Participants Achieving Clinical Response During Neo-Adjuvant Period by X-Ray/Mammography

    Clinical response was determined based on tumor measurements by sponsor in combination with tumor response assessment by investigator. Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment. Overall response is derived based on the sum total of breast tumors and all nodes examined.

    Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months

  6. Percentage of Participants Achieving Clinical Response During Neo-Adjuvant Period by Clinical Examination

    Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment. Primary breast tumor clinical response is based on primary breast tumor assessment. Overall response is derived based on the sum total of breast tumors and all nodes examined.

    Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months

  7. Time to Clinical Response During Neo-Adjuvant Treatment Period

    Time to clinical response was defined as the time from the date of first dose received to the date of assessment of clinical response. Time to Clinical response was determined by Kaplan-Meier estimates. Tumor assessments were made based on the RECIST criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment.

    Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months

  8. Percentage of Participants With Progressive Disease During Neo-Adjuvant Treatment Period

    Tumor assessments were made based upon the Response Evaluation Criteria in Solid Tumors (RECIST) criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: PD: if lesion is at least a 20 % increased from measurements at baseline. Percentage of participants along with 95% Confidence Interval (CI) for one sample binomial using Pearson-Clopper method were reported. Missing investigator assessments were considered as no progressive disease.

    Time frame: Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months

  9. Percentage of Participants Achieving Breast Conserving Surgery For Whom Mastectomy Was Planned

    Breast Conserving Surgery (BCS) was defined as quadrantectomy, lumpectomy, no surgery, sentinel node biopsy, axillary surgical resection or other method of avoiding mastectomy.

    Time frame: Surgery (Within 2 weeks after Cycle 4) Up to approximately 24 months

  10. Percentage of Participants Who Were Progression Free and Disease Free

    Disease-free survival (DFS) was defined as the time from first date of no disease to first documentation of PD or death. Participants without progression after surgery were considered Disease Free. Any evidence of contralateral disease in-situ was not considered as PD. Participants who were withdrawn from the study without documented progression and for whom evaluations were made, were censored at date of last assessment when participant was known to be disease-free. Progression-free survival (PFS) was defined as time from date of randomization to first documentation of PD or death. Any evidence of contralateral disease in-situ was not considered as PD. Participants who were withdrawn from study without documented progression and for whom evaluations were made, were censored at date of last assessment when the participant was known to be free from progressive disease. Participants without post baseline assessments but known to be alive were censored at the time of randomization.

    Time frame: Randomization up to a maximum of 329 weeks

  11. Progression Free and Disease Free Survival

    DFS was defined as the time from the first date of no disease (date of surgery) to the first documentation of PD or death. Participants without progression after surgery were considered Disease Free. Any evidence of contralateral disease in-situ was not considered as PD. PFS was defined as the time from the date of randomization to the first documentation of PD or death. Any evidence of contralateral disease in-situ was not considered as PD. DFS and PFS were determined using Kaplan-Meier estimates.

    Time frame: Randomization up to a maximum of 329 weeks

07

Results

Posted Jan 26, 2016

Participant flow

A total of 107, 107, 107, and 96 participants (total 417) were randomized to Arms Trastuzumab plus (+) Docetaxel (T+ D) , Trastuzumab+Pertuzumab+Docetaxel (T+Ptz+D), Trastuzumab+Pertuzumab (T+Ptz), and Pertuzumab+Docetaxel (Ptz+D), respectively and were included in intent-to-treat population (as randomized).

Neo-Adjuvant Treatment Period
Participant flow — Neo-Adjuvant Treatment Period
MilestoneTrastuzumab + DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Started10710710894
Completed1031029488
Not completed45146
Withdrew: Protocol violation1211
Withdrew: Refused treatment1141
Withdrew: Lost to follow-up1000
Withdrew: Death0100
Withdrew: Disease progression0172
Withdrew: Unknown reason1000
Withdrew: Adverse event0022
Adjuvant Treatment Period
Participant flow — Adjuvant Treatment Period
MilestoneTrastuzumab + DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Started1031029488
Completed98949074
Not completed58414
Withdrew: Disease progression3307
Withdrew: Refused treatment1115
Withdrew: Lost to follow-up1010
Withdrew: Adverse event0322
Withdrew: Unknown reason0100
Follow-Up Period
Participant flow — Follow-Up Period
MilestoneTrastuzumab + DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Started981029887
Completed77837860
Not completed21192027
Withdrew: Death4226
Withdrew: Disease progression6599
Withdrew: Refused treatment6202
Withdrew: Lost to follow-up3331
Withdrew: Unspecified reason2568
Withdrew: Violation of selection criteria at entry0201

Outcome measures

PrimaryPercentage of Participants Achieving Pathological Complete Response (pCR)

pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders

Time frame:
Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pathological Complete Response (pCR)
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Percentage of Participants Achieving Pathological Complete Response (pCR)29.0 (20.6 to 38.5)45.8 (36.1 to 55.7)16.8 (10.3 to 25.3)24.0 (15.8 to 33.7)
Statistical analysis
  • Trastuzumab+Docetaxel vs Trastuzumab+Pertuzumab+Docetaxel · Cochran-Mantel-Haenszel · p = 0.0094 (Cochran-Mantel-Haenszel test stratified by breast cancer type (operable, locally advanced, or inflammatory) and estrogen and or progesterone positivity (either positive versus both negative).) · Difference in response rates: 16.82 · 95% CI 3.5 to 30.1
  • Trastuzumab+Docetaxel vs Trastuzumab+Pertuzumab+Docetaxel · Cochran-Mantel-Haenszel · p = 0.0141 (P-value from Cochran-Mantel-Haenszel test, with Simes multiplicity adjustment.)
  • Trastuzumab+Docetaxel vs Trastuzumab+Pertuzumab · Cochran-Mantel-Haenszel · p = 0.0198 (Cochran-Mantel-Haenszel test stratified by breast cancer type (operable, locally advanced, or inflammatory) and estrogen and or progesterone positivity (either positive versus both negative).) · Difference in response rates: -12.15 · 95% CI -23.8 to -0.5
  • Trastuzumab+Docetaxel vs Trastuzumab+Pertuzumab · Cochran-Mantel-Haenszel · p = 0.0198 (P-value from Cochran-Mantel-Haenszel test, with Simes multiplicity adjustment.)
  • Trastuzumab+Pertuzumab+Docetaxel vs Pertuzumab+Docetaxel · Cochran-Mantel-Haenszel · p = 0.0010 (Cochran-Mantel-Haenszel test stratified by breast cancer type (operable, locally advanced, or inflammatory) and estrogen and or progesterone positivity (either positive versus both negative).) · Difference in response rates: -21.84 · 95% CI -35.1 to -8.5
  • Trastuzumab+Pertuzumab+Docetaxel vs Pertuzumab+Docetaxel · Cochran-Mantel-Haenszel · p = 0.0030 (P-value from Cochran-Mantel-Haenszel test, with Simes multiplicity adjustment.)
SecondaryPercentage of Participants Achieving Best Primary Tumor Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Disease Progression [PD]) During Neo-Adjuvant Treatment by X-Ray/Mammography

Tumor assessments were made based upon the Response Evaluation Criteria in Solid Tumors (RECIST) criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for primary breast tumor using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is greater than (\>)0 at screening or cycle 1 Day 1; PR: if measurement is at least a 30 percent (%) decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline.

Time frame:
Baseline up to Cycle 4 (assessed at, Baseline and Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Best Primary Tumor Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Disease Progression [PD]) During Neo-Adjuvant Treatment by X-Ray/Mammography
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
CR18.319.013.119.1
PR49.346.636.146.8
SD31.032.844.334.0
PD1.41.76.60.0
PrimaryPercentage of Participants Achieving pCR by Breast Cancer Type

pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Based on the type of breast cancer participants were categorized as those with 1. Operable breast cancer, 2. Inflammatory breast cancer and 3. Locally advanced breast cancer. Participants with invalid/missing pCR assessments were defined as non-responders.

Time frame:
Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving pCR by Breast Cancer Type
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Operable Breast Cancer (n=64,65,65,60)23.4 (13.8 to 35.7)47.7 (35.1 to 60.5)16.9 (8.8 to 28.3)26.7 (16.1 to 39.7)
Inflammatory Breast Cancer (n=7,10,7,5)14.3 (0.4 to 57.9)40.0 (12.2 to 73.8)28.6 (3.7 to 71.0)40.0 (5.3 to 85.3)
Locally Advance Breast Cancer (36,32,35,31)41.7 (25.5 to 59.2)43.8 (26.4 to 62.3)14.3 (4.8 to 30.3)16.1 (5.5 to 33.7)
PrimaryPercentage of Participants Achieving pCR by Hormone Receptor Status

pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants were classified as Estrogen and/or Progesterone positive (+ve), Estrogen and/or Progesterone negative (-ve) or receptor status unknown. Participants with invalid/missing pCR assessments were defined as non-responders.

Time frame:
Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving pCR by Hormone Receptor Status
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Estrogen and/or Progesterone +ve (n=50,50,51,46)20.0 (10.0 to 33.7)26.0 (14.6 to 40.3)5.9 (1.2 to 16.2)17.4 (7.8 to 31.4)
Estrogen and/or Progesterone -ve (n=57,57,55,50)36.8 (24.4 to 50.7)63.2 (49.3 to 75.6)27.3 (16.1 to 41.0)30.0 (17.9 to 44.6)
Receptor Status Unknown (0,0,1,0)NA (NA to NA)NA (NA to NA)0.0 (0.0 to 97.5)NA (NA to NA)
PrimaryPercentage of Participants Achieving pCR by Lymph Node Status

pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Lymph node status was defined as either negative lymph node at surgery or positive lymph node at surgery. Participants with invalid/missing pCR assessments were defined as non-responders.

Time frame:
Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving pCR by Lymph Node Status
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
pCR achieved and Negative Lymph Nodes at Surgery21.539.311.217.7
pCR achieved and Positive Lymph Nodes at Surgery7.56.55.66.3
PrimaryPercentage of Participants Achieving pCR by Presence or Absence of Residual Intraductal Carcinoma (DCIS) / Intalobular Carcinoma (LCIS)

pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders.

Time frame:
Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving pCR by Presence or Absence of Residual Intraductal Carcinoma (DCIS) / Intalobular Carcinoma (LCIS)
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
pCR Achieved and No residual DCIS/LCIS at Surgery16.836.49.317.7
pCR Achieved and Residual DCIS/LCIS at Surgery12.19.37.56.3
SecondaryPercentage of Participants Achieving Best Overall Response (CR, PR, SD or PD) During Neo-Adjuvant Period by X-Ray/Mammography

Tumor assessments were made based on the RECIST criteria - version 1.0 The overall response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.

Time frame:
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Best Overall Response (CR, PR, SD or PD) During Neo-Adjuvant Period by X-Ray/Mammography
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
CR18.318.912.718.6
PR49.349.134.546.5
SD31.030.245.534.9
PD1.41.97.30.0
SecondaryPercentage of Participants Achieving Best Primary Breast Tumor Response (CR, PR, SD or PD) During Neo-Adjuvant Period by Clinical Examination

Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for primary breast tumor using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.

Time frame:
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Best Primary Breast Tumor Response (CR, PR, SD or PD) During Neo-Adjuvant Period by Clinical Examination
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
CR23.230.716.720.9
PR56.657.451.050.5
SD20.211.930.428.6
PD0.00.02.00.0
SecondaryPercentage of Participants Achieving Best Overall Response (CR, PR, SD or PD) During the Neo-Adjuvant Period by Clinical Examination

Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.

Time frame:
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Best Overall Response (CR, PR, SD or PD) During the Neo-Adjuvant Period by Clinical Examination
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
CR21.625.011.215.9
PR59.863.055.158.0
SD17.512.031.626.1
PD1.00.02.00.0
SecondaryPercentage of Participants Achieving Clinical Response During Neo-Adjuvant Period by X-Ray/Mammography

Clinical response was determined based on tumor measurements by sponsor in combination with tumor response assessment by investigator. Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment. Overall response is derived based on the sum total of breast tumors and all nodes examined.

Time frame:
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response During Neo-Adjuvant Period by X-Ray/Mammography
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Primary Breast Tumor (n=71,58,61,47)67.6 (55.5 to 78.2)65.5 (51.9 to 77.5)49.2 (36.1 to 62.3)66.0 (50.7 to 79.1)
Overall Response (n=71,53,55,43)67.6 (55.5 to 78.2)67.9 (53.7 to 80.1)47.3 (33.7 to 61.2)65.1 (49.1 to 79.0)
SecondaryPercentage of Participants Achieving Clinical Response During Neo-Adjuvant Period by Clinical Examination

Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment. Primary breast tumor clinical response is based on primary breast tumor assessment. Overall response is derived based on the sum total of breast tumors and all nodes examined.

Time frame:
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response During Neo-Adjuvant Period by Clinical Examination
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Primary Breast Tumor (n=99,101,102,91)79.8 (70.5 to 87.2)88.1 (80.2 to 93.7)67.6 (57.7 to 76.6)71.4 (61.0 to 80.4)
Overall Response (n=97,100,98,88)81.4 (72.3 to 88.6)88.0 (80.0 to 93.6)66.3 (56.1 to 75.6)73.9 (63.4 to 82.7)
SecondaryTime to Clinical Response During Neo-Adjuvant Treatment Period

Time to clinical response was defined as the time from the date of first dose received to the date of assessment of clinical response. Time to Clinical response was determined by Kaplan-Meier estimates. Tumor assessments were made based on the RECIST criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment.

Time frame:
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Reported as:
Median · months
Time to Clinical Response During Neo-Adjuvant Treatment Period
monthsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Time to Clinical Response During Neo-Adjuvant Treatment Period6.3 (6.0 to 7.0)6.3 (4.0 to 7.0)6.9 (6.0 to 9.0)7.3 (6.0 to 9.0)
SecondaryPercentage of Participants With Progressive Disease During Neo-Adjuvant Treatment Period

Tumor assessments were made based upon the Response Evaluation Criteria in Solid Tumors (RECIST) criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: PD: if lesion is at least a 20 % increased from measurements at baseline. Percentage of participants along with 95% Confidence Interval (CI) for one sample binomial using Pearson-Clopper method were reported. Missing investigator assessments were considered as no progressive disease.

Time frame:
Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months
Reported as:
Number · percentage of participants
Percentage of Participants With Progressive Disease During Neo-Adjuvant Treatment Period
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Percentage of Participants With Progressive Disease During Neo-Adjuvant Treatment Period0.0 (0.0 to 3.4)0.9 (0.0 to 5.1)7.5 (3.3 to 14.2)2.1 (0.3 to 7.3)
SecondaryPercentage of Participants Achieving Breast Conserving Surgery For Whom Mastectomy Was Planned

Breast Conserving Surgery (BCS) was defined as quadrantectomy, lumpectomy, no surgery, sentinel node biopsy, axillary surgical resection or other method of avoiding mastectomy.

Time frame:
Surgery (Within 2 weeks after Cycle 4) Up to approximately 24 months
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Breast Conserving Surgery For Whom Mastectomy Was Planned
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Percentage of Participants Achieving Breast Conserving Surgery For Whom Mastectomy Was Planned22.6 (12.9 to 35.0)23.2 (13.0 to 36.4)18.0 (9.4 to 30.0)31.7 (20.3 to 45.0)
SecondaryPercentage of Participants Who Were Progression Free and Disease Free

Disease-free survival (DFS) was defined as the time from first date of no disease to first documentation of PD or death. Participants without progression after surgery were considered Disease Free. Any evidence of contralateral disease in-situ was not considered as PD. Participants who were withdrawn from the study without documented progression and for whom evaluations were made, were censored at date of last assessment when participant was known to be disease-free. Progression-free survival (PFS) was defined as time from date of randomization to first documentation of PD or death. Any evidence of contralateral disease in-situ was not considered as PD. Participants who were withdrawn from study without documented progression and for whom evaluations were made, were censored at date of last assessment when the participant was known to be free from progressive disease. Participants without post baseline assessments but known to be alive were censored at the time of randomization.

Time frame:
Randomization up to a maximum of 329 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Were Progression Free and Disease Free
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Progression Free82.284.174.875.0
Disease Free82.585.180.276.1
SecondaryProgression Free and Disease Free Survival

DFS was defined as the time from the first date of no disease (date of surgery) to the first documentation of PD or death. Participants without progression after surgery were considered Disease Free. Any evidence of contralateral disease in-situ was not considered as PD. PFS was defined as the time from the date of randomization to the first documentation of PD or death. Any evidence of contralateral disease in-situ was not considered as PD. DFS and PFS were determined using Kaplan-Meier estimates.

Time frame:
Randomization up to a maximum of 329 weeks
Reported as:
Median · percentage of participants
Progression Free and Disease Free Survival
percentage of participantsTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
PFSNA (NA to NA)71.0 (71.0 to 76.0)NA (NA to NA)NA (NA to NA)
DFSNA (NA to NA)67.2 (67.0 to 72.0)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Trastuzumab+Docetaxel vs Trastuzumab+Pertuzumab+Docetaxel · Cochran-Mantel-Haenszel · p = 0.2983 · Hazard ratio (hr): 0.69 · 95% CI 0.34 to 1.40HR is based on Cox proportional hazard regression stratified by breast cancer type and hormone positivity.
  • Trastuzumab+Docetaxel vs Trastuzumab+Pertuzumab · Cochran-Mantel-Haenszel · p = 0.4722 · Hazard ratio (hr): 1.25 · 95% CI 0.68 to 2.30HR is based on Cox proportional hazard regression stratified by breast cancer type and hormone positivity.
  • Trastuzumab+Pertuzumab+Docetaxel vs Pertuzumab+Docetaxel · Cochran-Mantel-Haenszel · p = 0.0268 · Hazard ratio (hr): 2.05 · 95% CI 1.07 to 3.93HR is based on Cox proportional hazard regression stratified by breast cancer type and hormone positivity.
  • Trastuzumab+Docetaxel vs Trastuzumab+Pertuzumab+Docetaxel · Cochran-Mantel-Haenszel · p = 0.1805 · Hazard ratio (hr): 0.60 · 95% CI 0.28 to 1.27HR is based on Cox proportional hazard regression stratified by breast cancer type and hormone positivity.
  • Trastuzumab+Docetaxel vs Trastuzumab+Pertuzumab · Cochran-Mantel-Haenszel · p = 0.5901 · Hazard ratio (hr): 0.83 · 95% CI 0.42 to 1.64HR is based on Cox proportional hazard regression stratified by breast cancer type and hormone positivity.
  • Trastuzumab+Pertuzumab+Docetaxel vs Pertuzumab+Docetaxel · Cochran-Mantel-Haenszel · p = 0.0250 · Hazard ratio (hr): 2.16 · 95% CI 1.08 to 4.32HR is based on Cox proportional hazard regression stratified by breast cancer type and hormone positivity.

Adverse events

Collected over Adverse events were recorded from the date of Screening until the clinical cut off date 20th October 2014 up to 7 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab+Docetaxel—21/107 (19.6%)107/107 (100%)
Trastuzumab+Pertuzumab+Docetaxel—22/107 (20.6%)105/107 (98.1%)
Trastuzumab+Pertuzumab—19/108 (17.6%)101/108 (93.5%)
Pertuzumab+Docetaxel—21/94 (22.3%)94/94 (100%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
Febrile neutropeniaBlood and lymphatic system disorders10/1078/1074/10812/94
NeutropeniaBlood and lymphatic system disorders1/1076/1073/1086/94
Left ventricular dysfunctionCardiac disorders0/1073/1070/1080/94
Pyelonephritis acuteInfections and infestations0/1072/1070/1080/94
Wound infectionInfections and infestations2/1070/1070/1080/94
DiarrhoeaGastrointestinal disorders2/1070/1070/1081/94
PyrexiaGeneral disorders1/1071/1072/1081/94
CellulitisInfections and infestations0/1070/1070/1081/94
SepsisInfections and infestations0/1070/1070/1081/94
Staphylococcal sepsisInfections and infestations0/1070/1070/1081/94
Most frequent other events
Showing 10 of 72
Most frequent other events
EventTrastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+Docetaxel
NeutropeniaBlood and lymphatic system disorders80/10764/10746/10867/94
AlopeciaSkin and subcutaneous tissue disorders75/10773/10759/10865/94
NauseaGastrointestinal disorders70/10771/10752/10861/94
DiarrhoeaGastrointestinal disorders40/10755/10746/10852/94
VomitingGastrointestinal disorders31/10739/10731/10837/94
FatigueGeneral disorders35/10735/10734/10837/94
RashSkin and subcutaneous tissue disorders26/10730/10722/10830/94
Mucosal inflammationGeneral disorders28/10733/10718/10828/94
General DisorderGeneral disorders17/10716/10715/10826/94
AstheniaGeneral disorders22/10729/10719/10823/94

Baseline characteristics

Intent-To-Treat (ITT) Population included all randomized participants who received any amount of study medication. Analysis was performed according to initial randomization.

Age, Continuous
Age, Continuous(years)Trastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+DocetaxelTotal
Mean50.9 ± 8.9449.6 ± 10.0549.7 ± 10.6748.9 ± 10.5049.8 ± 10.04
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab+DocetaxelTrastuzumab+Pertuzumab+DocetaxelTrastuzumab+PertuzumabPertuzumab+DocetaxelTotal
Female10710710796417
Male00000
08

Study locations

77 sites
  • Geelong Hospital; Andrew Love Cancer Centre
    Geelong, Victoria 3220, Australia
  • Mount Medical Center
    Perth, Western Australia 6000, Australia
  • Kaiser Franz Josef Spital; Iii. Medizinische Abt. Mit Onkologie
    Vienna, 1100, Austria
  • Medizinische Universität Wien; Univ.Klinik für Innere Medizin I
    Wien, 1090, Austria
  • Hospital de Caridade de Ijui; Oncologia
    Ijui, RS 98700-000, Brazil
  • Hospital Nossa Senhora da Conceicao
    Porto Alegre, RS 91350-200, Brazil
  • Clinica de Neoplasias Litoral
    Itajai, SC 88301-220, Brazil
  • Hospital Amaral Carvalho
    Jau, SP 17210-080, Brazil
  • Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia
    Santo Andre, SP 09060-650, Brazil
  • Instituto do Cancer Arnaldo Vieira de Carvalho - ICAVC; Pesquisa Clinica
    Sao Paulo, SP 01221-020, Brazil
  • Hospital Perola Byington
    Sao Paulo, SP 01317-000, Brazil
  • Inst. Brasileiro de Controle Ao Cancer; Oncologia Clinica / Quimioterapia
    Sao Paulo, SP 03102-002, Brazil
  • Instituto de Oncologia de Sorocaba - CEPOS
    Sorocaba, SP 18030-245, Brazil
  • Moncton Hospital
    Moncton, New Brunswick E1C 6Z8, Canada
  • Cancer Centre of Southeastern Ontario; Kingston General Hospital
    Kingston, Ontario K7L 5P9, Canada
  • University Health Network; Princess Margaret Hospital; Medical Oncology Dept
    Toronto, Ontario M5G 2M9, Canada
  • McGill University; Montreal General Hosptial; Oncology
    Montreal, Quebec H3G 1A4, Canada
  • CHU de Québec - Hôpital du Saint-Sacrement / ONCOLOGY
    Quebec, G1S 4L8, Canada
  • Hadassah Ein Karem Hospital; Oncology Dept
    Jerusalem, 91120-01, Israel
  • Meir Medical Center; Oncology
    Kfar-Saba, 4428164, Israel
  • Sourasky / Ichilov Hospital; Dept. of Oncology
    Tel Aviv, 6423906, Israel
  • Az. Osp. S. Orsola Malpighi; Istituto Di Oncologia Seragnoli
    Bologna, Emilia-Romagna 40138, Italy
  • Ospedale Regionale Di Parma; Divisione Di Oncologia Medica
    Parma, Emilia-Romagna 43100, Italy
  • Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia
    Udine, Friuli-Venezia Giulia 33100, Italy
  • ASST OVEST MILANESE; Oncologia Medica
    Legnano, Lombardia 20025, Italy
  • Ospedale San Raffaele, Servizio di Oncologia e Chemioterapia
    Milano, Lombardia 20132, Italy
  • Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1
    Milano, Lombardia 20133, Italy
  • Ospedale Calvi di Noale; U.O. Complessa di Oncologia ed Ematologia Oncologica
    Mirano, Veneto 30035, Italy
  • Polo Ospedaliero Santorso
    Santorso, Veneto 36014, Italy
  • Ospedale Di Vicenza; Nefrologia, Oncologia Medica
    Vicenza, Veneto 36100, Italy
  • Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology
    Seoul, 03080, Korea, Republic of
  • Samsung Medical Centre; Division of Hematology/Oncology
    Seoul, 135-710, Korea, Republic of
  • Hospital Miguel Hidalgo
    Aguascalientes, 20230, Mexico
  • ARKE Estudios Clínicos S.A. de C.V.
    Mexico City, 06700, Mexico
  • Issstep Puebla, ; Oncology
    Puebla, 72530, Mexico
  • Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica
    Arequipa, 5154, Peru
  • Hospital Nacional Edgardo Rebagliati Martins; Oncologia
    Lima, 11, Peru
  • Samodzielny Publiczny Kliniczny Nr 1 W Lublinie; Klinika Chirurgii Onkologicznej
    Lublin, 20-081, Poland
  • COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej
    Lublin, 20-090, Poland
  • Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o.
    Olsztyn, 10-513, Poland
  • Oddzial Chemioterapii Szpitala Klinicznego Nr 1 w Poznaniu
    Poznan, 60-569, Poland
  • NZOZ Centrum Medyczne HCP Sp. z o.o.
    Poznan, 61-485, Poland
  • Central Hospital of Military School of Medicine; Oncology
    Warszawa, 00-909, Poland
  • Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii
    Warszawa, 02-781, Poland
  • FSBI "Scientific Research Institute of Oncology named after N.N.Petrov" Ministry of Health of RF
    St Petersburg, Leningrad 197758, Russian Federation
  • SI of Healthcare Kazan Oncology Dispensary
    Kazan, 420111, Russian Federation
  • Russian Oncology Research Center n.a. N.N. Blokhin Dpt of Clinical Pharmacology and Chemotherapy
    Moscow, 115478, Russian Federation
  • NSI of Healthcare Central Clinical Hospital #2 n.a. N.A.Semashko of the Russian Railways
    Moscow, 129128, Russian Federation
  • State Institution Of Healthcare Republican Oncology Dispensary
    Petrozavodsk, 185007, Russian Federation
  • State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary
    Pyatigorsk, 357502, Russian Federation
  • SBI for HPE "Ryazan State Medical University n.a. I.P. Pavlov" of MoH of RF
    Ryazan, 390011, Russian Federation
  • SBI of Healthcare Samara Regional Clinical Oncology Dispensary
    Samara, 443031, Russian Federation
  • SI of HealthCare Oncologic Dispensary #2 of department of healthcare of Krasnodar region
    Soshi, 354057, Russian Federation
  • SBI of Healthcare Leningrad Regional Oncology Dispensary
    St Petersburg, 191104, Russian Federation
  • Ulyanovsk Regional Oncology Dispensary; Chemotherapy
    Ulyanovsk, ND, Russian Federation
  • Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
    Sabadell, Barcelona 08208, Spain
  • Hospital de Cruces; Servicio de Oncologia
    Barakaldo, Vizcaya 48903, Spain
  • Hospital Universitario Reina Sofia; Servicio de Oncologia
    Cordoba, 14004, Spain
  • Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
    Madrid, 28007, Spain
  • Hospital Ramon y Cajal; Servicio de Oncologia
    Madrid, 28034, Spain
  • Hospital Universitario La Paz; Servicio de Oncologia
    Madrid, 28046, Spain
  • Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
    Valencia, 46010, Spain
  • Hospital Universitario Miguel Servet; Servicio Oncologia
    Zaragoza, 50009, Spain
  • Karolinska Hospital; Oncology - Radiumhemmet
    Stockholm, 17176, Sweden
  • Akademiska sjukhuset, Onkologkliniken
    Uppsala, 75185, Sweden
  • Kantonsspital Baden; Frauenklinik
    Baden, 5405, Switzerland
  • Brustzentrum
    Zürich, 8008, Switzerland
  • VETERANS GENERAL HOSPITAL; Department of General Surgery
    Taipei, 00112, Taiwan
  • National Taiwan Uni Hospital; Dept of Oncology
    Taipei, 100, Taiwan
  • Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology
    Taipei, 112, Taiwan
  • Chulalongkorn Hospital; Medical Oncology
    Bangkok, 10330, Thailand
  • Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
    Bangkok, 10700, Thailand
  • Prince of Songkla Uni ; Unit of Medical Oncology
    Songkhla, 90110, Thailand
  • Dokuz Eylul Uni Medical Faculty; Oncology Dept
    Izmir, 35340, Turkey
  • Hacettepe Uni Medical Faculty Hospital; Oncology Dept
    Sıhhiye, ANKARA, 06100, Turkey
  • Walsgrave Hospital; Dept of Oncology
    Coventry, CV2 2DX, United Kingdom
  • Christie Hospital; Breast Cancer Research Office
    Manchester, M20 4QL, United Kingdom
09

References and documents

Publications

  • Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Res. 2017 Feb 9;19(1):16. doi: 10.1186/s13058-017-0806-9. PubMed 28183321 ↗
  • Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, Baselga J. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol. 2017 Apr 1;28(4):761-768. doi: 10.1093/annonc/mdw695. Erratum In: Ann Oncol. 2018 Apr 1;29(4):1075. doi: 10.1093/annonc/mdx336. Ann Oncol. 2018 Jul 1;29(7):1607. doi: 10.1093/annonc/mdx802. Ann Oncol. 2019 Aug 1;30(8):1404. doi: 10.1093/annonc/mdy538. PubMed 28057664 ↗
  • Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzu D, McNally V, Douthwaite H, Ross G, Valagussa P. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016 Jun;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7. Epub 2016 May 11. PubMed 27179402 ↗
  • Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6. PubMed 22153890 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2006 to primary completion in Sep 2014, 98 months.

Results were first posted in Jan 2016, 1 year 4 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 98 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2007
First posted
Oct 17, 2007
StartActual
Jun 26, 2006
Primary completionActual
Sep 22, 2014
CompletionActual
Sep 22, 2014
Results first posted
Jan 26, 2016
Last update
Aug 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00545688
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 17, 2007
Start date
Jun 26, 2006
Primary completion
Sep 22, 2014
Completion
Sep 22, 2014
Results posted
Jan 26, 2016
Last update
Aug 15, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab · Docetaxel · Pertuzumab

Start the discussion